(30 days)
Not Found
No
The summary describes a physical implant device and its mechanical properties, with no mention of software, algorithms, or data processing that would indicate AI/ML.
Yes
The device is indicated for intervertebral body fusion to treat degenerative disc disease, which is a therapeutic purpose.
No
The device is an intervertebral body fusion device designed for use with bone graft and supplemental fixation to stabilize spinal segments and promote fusion, which is a therapeutic function, not a diagnostic one.
No
The device description clearly states it is a physical intervertebral body fusion device made from PEEK-Optima with tantalum or titanium markers, and includes mechanical testing of the physical device.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This information is used for diagnosis, monitoring, or screening.
- FuseLOX Device Function: The FuseLOX Lumbar Interbody Fusion Device is a physical implant designed to be surgically placed in the lumbar spine to facilitate bone fusion. It is a therapeutic device, not a diagnostic one.
- Intended Use: The intended use clearly states it's for "intervertebral body fusion" in patients with degenerative disc disease. This is a surgical intervention, not a diagnostic test.
- Device Description: The description details the materials and design of a physical implant, not a device for analyzing biological samples.
The information provided describes a surgical implant used for treatment, which falls under the category of a medical device, but specifically not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The FuseLOX Lumbar Interbody Fusion Device is an intervertebral body fusion device indicated for intervertebral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.
The FuseLOX Lumbar Interbody Fusion Device is designed for use with autograft to facilitate fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine.
Product codes
MAX
Device Description
The FuseLOX Lumbar Interbody Fusion System is an intervertebral body fusion device for use with autogenous bone graft in the intervertebral disc space to stabilize spinal segments and promote fusion. The device is made from PEEK-Optima with tantalum or titanium markers. The devices are provided in lordotic and convex configurations with heights ranging from 7-14mm in 1mm increments. Each device has a hollow core to receive bone graft. Placement is achieved with a series of device specific instruments provided.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Lumbar spine from L2 to S1
Indicated Patient Age Range
skeletally mature
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Mechanical testing of the subject device consisted of static and dynamic compression, static compression shear, static torsion and subsidence according to ASTM F2077 and ASTM F2267.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Pivotec Lumbar Interbody Fusion System (K092017), Aleutian IBF System (K113138), and Lumbar I/F Cage (P960025)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc)
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
Captiva Spine FuseLOX Lumbar Interbody Fusion System 510(k)
510(k) Summary according to 807.92(c) FuseLOX Interbody Fusion System
| Date: | August 20, 2012 |
|---|---|
| Submitter Contact: | Dale Mitchell |
| Captiva Spine | |
| 967 Alternate A1A #1 | |
| Jupiter, FL 33477 | |
| 877-772-5571 | |
| 866-318-3224 | |
| Regulatory Contact: | Rich Jansen, Pharm. D. |
| Silver Pine Consulting, LLC | |
| 612-281-5505 | |
| richj@s-pineconsulting.com | |
| Trade Name: | FuseLOX Lumbar Interbody Fusion System |
| Product Class: | Class II |
| Classification: | 888.3080 Intervertebral Body Fusion Device |
| Product Codes: | MAX |
| Panel Code: | 87 |
| Predicate Device(s): | Pivotec Lumbar Interbody Fusion System (K092017), Aleutian |
| IBF System (K113138), and Lumbar I/F Cage (P960025) |
OCT 2 5 2012Reason for this Submission: This Special 510(k) involves several changes to the previously cleared Pivotec System that allow for:
- The marketing name for this device will be FuseLOX Lumbar. It is a line extension for 1. the Pivotec Lumbar Interbody Fusion Device (K092017). The Pivotec device is inserted using a pivoting insertion tool for implant delivery, while the FuseLOX Lumbar devices will offer a non-pivoting, threaded insertion tool. The reason for the market name change is to distinguish the two insertion options.
-
- Offering two new device configurations, the FuseLOX Lumbar Lordotic and the FuseLOX Lumbar Convex.
-
- Added new, non-pivoting inserter design to mate with the FuseLOX Lumbar design.
-
- New trial instrument design consistent with the FuseLOX Lumbar design.
-
- New tray design to accommodate either Pivotec or FuseLOX Lumbar system's inserter and implant/trial caddy, along with all shared instrumentation.
Page 1 of 2
1
Indications for Use/Intended Use: The FuseLOX Lumbar Interbody Fusion Device is an intervertebral body fusion device indicated for intervertebral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.
The FuseLOX Lumbar Interbody Fusion Device is designed for use with autograft to facilitate fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine.
Device Description: The FuseLOX Lumbar Interbody Fusion System is an intervertebral body fusion device for use with autogenous bone graft in the intervertebral disc space to stabilize spinal segments and promote fusion. The device is made from PEEK-Optima with tantalum or titanium markers. The devices are provided in lordotic and convex configurations with heights ranging from 7-14mm in 1mm increments. Each device has a hollow core to receive bone graft. Placement is achieved with a series of device specific instruments provided.
Performance Testing: Mechanical testing of the subject device consisted of static and dynamic compression, static compression shear, static torsion and subsidence according to ASTM F2077 and ASTM F2267.
Conclusion: The documentation provided demonstrates that the FuseLOX Lumbar Interbody Fusion Device is substantially equivalent to the predicate device listed above. This conclusion is based on the devices' similarities in materials, design, indications for use, clinical application and mechanical function. Captiva Spine concludes that the changes to the system do not introduce any new risks and therefore, the system is Substantially Equivalent to the predicate device, Pivotec Lumbar Interbody Fusion Device.
Page 2 of 2
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo features a stylized depiction of an eagle or bird-like figure, with three curved lines forming the body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the bird. The logo is black and white.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Captiva Spine % Silver Pine Consulting, LLC Rich Jansen, Pharm. D. 13540 Guild Avenue Apple Valley, Minnesota 55124
OCT 25 2012
Re: K122956
Trade/Device Name: FuseLOX Lumbar Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: September 24, 2012 Received: September 25, 2012
Dear Dr. Jansen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
3
Page 2 -Rich Jansen, Pharm. D.
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Euil Keith
A Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Captiva Spine FuseLOX Lumbar Interbody Fusion System 510(k)
Statement of Indications for Use
510(k) Number (if known): k122295e
The FuseLOX Lumbar Interbody Fusion Device is an intervertebral body fusion device indicated for interverterral body fusion at one level or two contiguous levels in the lumbar spine from L2 to S1 in patients with degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at the involved level(s). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. The FuseLOX Lumbar Interbody Fusion Device is designed for use with autograft to facilitate fusion and is intended for use with supplemental fixation systems cleared for use in the lumbar spine.
Prescription Use で (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Cal-bp
(Division Sign Off)
(Division Sign-Off) Division of Surgical, Orthopedic, and Restorative Devices
K122956 510(k) Number_